18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Autor: Ralf S. Eschbach, Philipp M. Kazmierczak, Maurice M. Heimer, Andrei Todica, Heidrun Hirner-Eppeneder, Moritz J. Schneider, Georg Keinrath, Olga Solyanik, Jessica Olivier, Wolfgang G. Kunz, Maximilian F. Reiser, Peter Bartenstein, Jens Ricke, Clemens C. Cyran

Publikováno v: Cancer Imaging, Vol 18, Iss 1, Pp 1-11 (2018)

Abstract Background The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of BRAF-V600-mutant human melanoma monitored by 18F–FDG-PET/CT and diffusion-weighted MRI (DW-MRI). Methods Hum

Externí odkaz: https://doaj.org/article/5e60894928dc4558b574f6b99e932308

Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.

Autor: Ralf Stefan Eschbach, Dirk-Andre Clevert, Heidrun Hirner-Eppeneder, Michael Ingrisch, Matthias Moser, Jessica Schuster, Dina Tadros, Moritz Schneider, Philipp Maximilian Kazmierczak, Maximilian Reiser, Clemens C Cyran

Publikováno v: PLoS ONE, Vol 12, Iss 1, p e0169323 (2017)

To investigate contrast-enhanced ultrasound (CEUS) with VEGFR2-targeted microbubbles for monitoring therapy effects of regorafenib on experimental colon carcinomas in rats with correlation to dynamic contrast-enhanced MRI (DCE-MRI) and immunohistoche

Externí odkaz: https://doaj.org/article/a982e3c15e5d4895b813c5013aab1438

Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.

Autor: Ralf S Eschbach, Wolfgang P Fendler, Philipp M Kazmierczak, Marcus Hacker, Axel Rominger, Janette Carlsen, Heidrun Hirner-Eppeneder, Jessica Schuster, Matthias Moser, Lukas Havla, Moritz J Schneider, Michael Ingrisch, Lukas Spaeth, Maximilian F Reiser, Konstantin Nikolaou, Clemens C Cyran

Publikováno v: PLoS ONE, Vol 10, Iss 2, p e0115543 (2015)

OBJECTIVES:To investigate a multimodal, multiparametric perfusion MRI / 18F-fluoro-deoxyglucose-(18F-FDG)-PET imaging protocol for monitoring regorafenib therapy effects on experimental colorectal adenocarcinomas in rats with immunohistochemical vali

Externí odkaz: https://doaj.org/article/05d81c2ac117462c838bc0af495c80fb

A Multi-Scale and Multi-Technique Approach for the Characterization of the Effects of Spatially Fractionated X-ray Radiation Therapies in a Preclinical Model

Autor: Cinzia Giannini, Oliver Bunk, Marianna Alunni-Fabbroni, Giacomo E. Barbone, Stefan Bartzsch, Alberto Mittone, Lucie Sancey, Heidrun Hirner-Eppeneder, Armin Giese, Dmitry Karpov, Alberto Bravin, Audrey Bouchet, Mariele Romano, Alicia Eckhardt, Jens Ricke, Viktoria Ruf, Julien Dinkel, Paola Coan

Publikováno v: Cancers
Volume 13
Issue 19
Cancers 13:4953 (2021)
Cancers, Vol 13, Iss 4953, p 4953 (2021)
'Cancers ', vol: 13, pages: 4953-1-4953-30 (2021)
Cancers, MDPI, 2021, 13 (19), pp.4953. ⟨10.3390/cancers13194953⟩
Cancers 13(19), 4953 (2021). doi:10.3390/cancers13194953

Simple Summary This study aims at using a multi-technique approach to detect and analyze the effects of high dose rate spatially fractionated radiation therapies and to compare them to seamless broad beam irradiation targeting healthy and glioblastom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::766cb0ae2c9326770bbf2b420ff2ec79

18F–FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma

Autor: Georg Keinrath, Jens Ricke, Maurice Heimer, Wolfgang G. Kunz, Ralf S. Eschbach, Andrei Todica, Philipp M. Kazmierczak, Peter Bartenstein, Clemens C. Cyran, Heidrun Hirner-Eppeneder, Maximilian F. Reiser, Moritz Schneider, Jessica Olivier, Olga Solyanik

Publikováno v: Cancer Imaging, Vol 18, Iss 1, Pp 1-11 (2018)
Cancer Imaging

Background The purpose of the study was to investigate a novel BRAF and CDK 4/6 inhibitor combination therapy in a murine model of BRAF-V600-mutant human melanoma monitored by 18F–FDG-PET/CT and diffusion-weighted MRI (DW-MRI). Methods Human BRAF-V

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e48a55f92488cb5ac30abf0e3512bbaa
https://doi.org/10.1186/s40644-018-0135-y